249 related articles for article (PubMed ID: 34804035)
1. Generation of an NFκB-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell Therapy.
Rudek LS; Zimmermann K; Galla M; Meyer J; Kuehle J; Stamopoulou A; Brand D; Sandalcioglu IE; Neyazi B; Moritz T; Rossig C; Altvater B; Falk CS; Abken H; Morgan MA; Schambach A
Front Immunol; 2021; 12():751138. PubMed ID: 34804035
[TBL] [Abstract][Full Text] [Related]
2. Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines.
Kulemzin SV; Matvienko DA; Sabirov AH; Sokratyan AM; Chernikova DS; Belovezhets TN; Chikaev AN; Taranin AV; Gorchakov AA
BMC Med Genomics; 2019 Mar; 12(Suppl 2):44. PubMed ID: 30871576
[TBL] [Abstract][Full Text] [Related]
3. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
4. Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors.
Suerth JD; Morgan MA; Kloess S; Heckl D; Neudörfl C; Falk CS; Koehl U; Schambach A
J Mol Med (Berl); 2016 Jan; 94(1):83-93. PubMed ID: 26300042
[TBL] [Abstract][Full Text] [Related]
5. Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-G
Zimmermann K; Kuehle J; Dragon AC; Galla M; Kloth C; Rudek LS; Sandalcioglu IE; Neyazi B; Moritz T; Meyer J; Rossig C; Altvater B; Eiz-Vesper B; Morgan MA; Abken H; Schambach A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32041222
[TBL] [Abstract][Full Text] [Related]
6. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
Morgan MA; Kloos A; Lenz D; Kattre N; Nowak J; Bentele M; Keisker M; Dahlke J; Zimmermann K; Sauer M; Heuser M; Schambach A
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372571
[TBL] [Abstract][Full Text] [Related]
7. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
[TBL] [Abstract][Full Text] [Related]
8. GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD
Glienke W; Dragon AC; Zimmermann K; Martyniszyn-Eiben A; Mertens M; Abken H; Rossig C; Altvater B; Aleksandrova K; Arseniev L; Kloth C; Stamopoulou A; Moritz T; Lode HN; Siebert N; Blasczyk R; Goudeva L; Schambach A; Köhl U; Eiz-Vesper B; Esser R
Front Immunol; 2022; 13():839783. PubMed ID: 35401506
[TBL] [Abstract][Full Text] [Related]
9. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
11. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
12. Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.
Kang CH; Kim Y; Lee SM; Choi SU; Park CH
Anticancer Res; 2021 Apr; 41(4):1811-1819. PubMed ID: 33813386
[TBL] [Abstract][Full Text] [Related]
13. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
14. CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation.
Dragon AC; Zimmermann K; Nerreter T; Sandfort D; Lahrberg J; Klöß S; Kloth C; Mangare C; Bonifacius A; Tischer-Zimmermann S; Blasczyk R; Maecker-Kolhoff B; Uchanska-Ziegler B; Abken H; Schambach A; Hudecek M; Eiz-Vesper B
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33127653
[TBL] [Abstract][Full Text] [Related]
15. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
16. Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4.
Jamali A; Hadjati J; Madjd Z; Mirzaei HR; Thalheimer FB; Agarwal S; Bonig H; Ullrich E; Hartmann J
Front Immunol; 2020; 11():2028. PubMed ID: 32983147
[TBL] [Abstract][Full Text] [Related]
17. Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells.
Murakami T; Nakazawa T; Natsume A; Nishimura F; Nakamura M; Matsuda R; Omoto K; Tanaka Y; Shida Y; Park YS; Motoyama Y; Nakagawa I; Yamada S; Tamura K; Takeshima Y; Takamura Y; Wakabayashi T; Nakase H
Anticancer Res; 2018 Sep; 38(9):5049-5056. PubMed ID: 30194149
[TBL] [Abstract][Full Text] [Related]
18. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
19. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
[TBL] [Abstract][Full Text] [Related]
20. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]